Biotech companies are racing to find Ozempic 2.0, hoping for a slice of a multi-billion-dollar industry. A few stand-out ...

Eli Lilly (NYSE: LLY) sells a broad range of pharmaceuticals treating various diseases, but one portfolio in particular has ...

Eli Lilly said on Wednesday its weight-loss drug helped nearly 99% of patients remain diabetes-free after three years of ...

Below, I'll break down what's going on at Viking and explain how the company may emerge as a competitive force in the weight ...

In the United Kingdom, the government is hoping weight loss drugs might improve public finances, eyeing their use to help ...

A Goldman Sachs economist has suggested that the US economy could experience accelerated growth with increased use of GLP-1 ...

The headline trial results will be closely monitored by pharmaceutical industry experts. Shares in Novo Nordisk, which ...

If you looked solely at its stock price, you might get the idea that Eli Lilly (NYSE ... Learn more here. Lilly's newest cash ...

The chart below compares the forward price to earnings (P/E) ratio of AstraZeneca to multiples in a peer set of leading ...

Company behind weight loss drug Mounjaro, Lilly, has issued an official statement after British woman, Susan McGowan, died ...

The drug is a promising potential competitor in the weight loss drug market that is designed to be taken monthly rather than ...

Eli Lilly's tirzepatide cut the risk of developing type 2 diabetes for people with pre-diabetes by 94%, according to new ...